MedPath

Practice of Ventilation in Middle-Income Countries

Completed
Conditions
Respiratory Distress Syndrome, Adult
Acute Respiratory Failure
Mechanical Ventilation
Registration Number
NCT03188770
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Brief Summary

The purpose of this international, multicenter service review is to describe and compare ventilation management in patients at risk of acute respiratory distress syndrome (ARDS) versus patients not at risk and patients with established ARDS, and to ascertain whether certain ventilator settings and ventilation parameters are associated with pulmonary complications or development of ARDS after start of ventilation in patients in intensive care units (ICUs) in Asian countries.

Participating centers will include adult patients undergoing mechanical ventilation in the ICU during a 28-day period. Patients' data will be collected during the first 7 days in the ICU, or until ICU discharge. Follow up is until ICU discharge. The primary outcome includes two main ventilator settings, i.e., tidal volume and the level of positive end-expiratory pressure. Secondary endpoints are development of ARDS in patients without ARDS at the onset of mechanical ventilation, worsening of ARDS in patients with ARDS at the onset of mechanical ventilation, pulmonary infection, other pulmonary complications, need for tracheostomy, duration of ventilation, length of ICU stay and ICU mortality.

Detailed Description

Rationale: scarce information exists on management of mechanical ventilation in intensive care unit (ICU) patients in low- and middle-income countries.

Objective:The primary objective is to describe and compare ventilation management in patients at risk of ARDS versus individuals not at risk, and patients with established ARDS, and to ascertain whether certain ventilation settings are associated with a higher incidence of developing ARDS in patients in ICUs in Asia. PRoVENT-iMIC secondary objectives are to determine the epidemiological characteristics and clinical outcomes of patients at risk of ARDS in ICUs in Asia according to the ventilation practice applied.

Primary hypothesis: a large proportion of patients at risk of ARDS in ICUs in Asia do not receive so-called protective ventilation, defined as tidal volume \< 8 ml/kg predicted body weight and a level of positive end-expiratory pressure of at least 5 cm H2O.

Secondary hypothesis: in ICUs in Asia a large proportion of patients is at risk of ARDS, as stratified by a Lung Injury Prediction Score of ≥4.

Study design: an international multicenter service review focusing on ICUs in selected middle-income Asian countries.

Population: consecutive intubated and ventilated ICU patients.

Methods: Patients in participating ICUs will be screened daily during a 28-day period. A registry of limited demographic data will be compiled on all screened patients. Collection of ventilation characteristics is restricted to the first three days. The first seven days or up to death, whichever comes first, will be used for collection of patient demographics (on day of admission), development of ARDS and other pulmonary complications. All patients will be followed until ICU-discharge to determine length of stay in ICU and ICU mortality. The inclusion period will be flexible for participating centers and determined at a later stage together with the study-coordinator. Data will be coded by a patient identification number of which the code will be kept safe at the local sites. The data will be transcribed by local investigators onto an internet based electronic case report form (https://www.project-redcap.org).

Centers: about 60 Asian ICUs from ten countries are expected to participate in this international multicenter study. Each participating center will recruit \~ 50 patients.

Ethics Approval: The Oxford Tropical Research Ethical Committee has evaluated the study and considered it exempt from ethical review on the 1st of June 2017. National coordinators will be responsible for clarifying the need for ethics approval and applying for this where appropriate according to local policy. Centers will not be permitted to record data unless ethics approval or an equivalent waiver is in place.

Monitoring: Due to the observational nature of the study, a Data Safety and Monitoring Board is not necessary.

Sample Size Calculation: a formal sample size calculation was not performed, seen the largely descriptive character of this investigation. 3000 patients are expected to be enrolled in the study period, which will be sufficient to test the hypotheses.

Statistical Analysis: Patient characteristics will be compared and described by appropriate statistics. Student's t-test or Mann-Whitney U-tests are used to compare continuous variables and chi-squared tests are used for categorical variables. Data are expressed as means (SD), medians (interquartile range) and proportions as appropriate. Comparisons between and within groups are performed using one-way ANOVA and post-hoc analyses for continuous variables.

The primary analysis concerns the determination of (variation of) tidal volume and PEEP levels in patients without ARDS. These are compared between predefined patient groups: patients at no risk for ARDS, patients at risk for ARDS, patients with mild ARDS, and patients with moderate or severe ARDS.

To identify potential factors associated with outcome like development of ARDS, or worsening of ARDS, development of pulmonary complications, duration of ventilation, or death, univariate analyses are performed. A multivariate logistic regression model is used to identify independent risk factors. A stepwise approach is used to enter new terms into the model, with a limit of p \< 0.2 to enter the terms. Time to event variables are analyzed using Cox regression and visualized by Kaplan-Meier.

Organization: The study is conducted by the PROtective VEntilation Network (PROVENet). National co-ordinators will lead the project within individual nations and identify participating hospitals, translate study paperwork, distribute study paperwork and ensure necessary regulatory approvals are in place. They provide assistance to the participating clinical sites in trial management, record keeping and data management. Local coordinators in each site will supervise data collection and ensure adherence to Good Clinical Practice during the trial.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1315
Inclusion Criteria
  • Admitted to an ICU participating in this study
  • Intubated in the ICU, or in the emergency room, general ward, or operation room before the present ICU admission
Exclusion Criteria
  • Age < 18 years
  • Patients under invasive mechanical ventilation previous to the 28-day period of inclusion
  • Patients transferred from another hospital under invasive mechanical ventilation
  • Receiving only non-invasive ventilation (i.e., patient never received invasive ventilation during the present admission)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Tidal volume sizeDay 1 to Day 3 from initiation of mechanical ventilation

Tidal volume size in milliliters per kilogram of predicted body weight

Positive end-expiratory pressureDay 1 to Day 3 from initiation of mechanical ventilation

Pressure in cm of water

Secondary Outcome Measures
NameTimeMethod
Inspired Oxygen ConcentrationDay 1 to Day 3 from initiation of mechanical ventilation

expressed as fraction of inspired oxygen

Peak pressureDay 1 to Day 3 from initiation of mechanical ventilation

Peak away pressure in cm of water

Driving pressureDay 1 to Day 3 from initiation of mechanical ventilation

pressure in cm of water

Patients at risk of ARDSOn the date of inclusion

Risk of ARDS is stratified using the Lung Injury Prediction Score.

Length of stay in ICUUntil day 35 from study initiation

Time between admission and discharge or death

Plateau pressureDay 1 to Day 3 from initiation of mechanical ventilation

Pressure in cm of water

Development of ARDSFrom date of inclusion until the date of first documented development of ARDS or date of ICU discharge or death from any cause, whichever came first, assessed up to 7 days

Development of ARDS in patients without ARDS at the onset of mechanical ventilation. Patients are defined as having ARDS if they meet the Berlin criteria for ARDS

Respiratory RateDay 1 to Day 3 from initiation of mechanical ventilation

in breaths per minute

Pulmonary infectionFrom date of inclusion until the date of first documented pulmonary complication or date of ICU discharge or death from any cause, whichever came first, assessed up to 7 days

defined as need of new antibiotics in the presence of new or changed lung opacities on chest X-ray and/or new or changed sputum plus at least one of the following criteria: 1) temperature \> 38.3 ºC; or 2) WBC count \> 12,000

Minute VolumeDay 1 to Day 3 from initiation of mechanical ventilation

expressed as liters per minute

Other Pulmonary complicationsFrom date of inclusion until the date of first documented pulmonary complication or date of ICU discharge or death from any cause, whichever came first, assessed up to 7 days

pneumothorax, pleural effusions, cardiogenic pulmonary edema, new pulmonary infiltrates, and atelectasis

Worsening of ARDSFrom date of inclusion until the date of first documented worsening of ARDS or date of ICU discharge or death from any cause, whichever came first, assessed up to 7 days

Defined as any worsening in the degree of severity according to Berlin criteria.

Need for tracheostomyFrom date of inclusion until the date of first documented tracheostomy procedure or date of ICU discharge or death from any cause, whichever came first, assessed up to 7 days

Need for tracheostomy during ICU stay

All-cause ICU mortalityUntil day 35 from study initiation

Any death during ICU stay

Duration of mechanical ventilationUntil day 35 from study initiation

time between orotracheal intubation and successful extubation;note: in case of intermittent MV via a tracheostomy, every day a patient needs MV counts as one extra day of MV, irrespective of duration of MV that specific day; in case of non-invasive ventilation (CPAP and/or BIPAP), the duration will be assessed separated from the assessment of invasive mechanical ventilation.

Trial Locations

Locations (51)

Chittagong Medical College Hospital

🇧🇩

Chittagong, Bangladesh

Rajshahi Medical College Hospital

🇧🇩

Rajshahi, Bangladesh

Dhaka Medical College Hospital

🇧🇩

Dhaka, Bangladesh

Shifa International Hospital

🇵🇰

Islamabad, Pakistan

Modarres Hospital

🇮🇷

Tehran, Iran, Islamic Republic of

Pars Hospital

🇮🇷

Tehran, Iran, Islamic Republic of

Bangabandhu Sheikh Mujib Medical University

🇧🇩

Dhaka, Bangladesh

BIRDEM General Hospital

🇧🇩

Dhaka, Bangladesh

St. John's Medical College

🇮🇳

Bangalore, India

Bharati Vidyapeeth Medical College

🇮🇳

Pune, India

Patan Academy of Health Sciences

🇳🇵

Katmandou, Nepal

Aga Khan University SICU

🇵🇰

Karachi, Pakistan

Masih Daneshvari Hospital

🇮🇷

Tehrān, Iran, Islamic Republic of

Monash University

🇲🇾

Johor Bahru, Malaysia

Hospital Kuala Lumpur

🇲🇾

Kuala Lumpur, Malaysia

Mohamad Irfan Bin Othman Jailani

🇲🇾

Kuala Lumpur, Malaysia

International Islamic University Medical Center

🇲🇾

Kuantan, Malaysia

North West General Hospital

🇵🇰

Peshawar, Pakistan

Batticaloa Base Hospital

🇱🇰

Batticaloa, Sri Lanka

Lanka Hospital

🇱🇰

Colombo, Sri Lanka

Vajira Hospital

🇹🇭

Bangkok, Thailand

Chiang Mai Medical ICU

🇹🇭

Chiang Mai, Thailand

Srinakharinwirot University

🇹🇭

Ongkharak, Thailand

Sylhet MAG Osmani Medical College Hospital

🇧🇩

Sylhet, Bangladesh

Indira Gandhi Memorial Hospital

🇲🇻

Malè, Maldives

National Hospital Sri Lanka MICU

🇱🇰

Colombo, Sri Lanka

National Hospital Sri Lanka SICU

🇱🇰

Colombo, Sri Lanka

Ramathibodi Hospital

🇹🇭

Bangkok, Thailand

Ispat General Hospital

🇮🇳

Raurkela, Odisha, India

Allied Hospital

🇵🇰

Faisalābad, Pakistan

PIMS

🇵🇰

Islamabad, Pakistan

Patel Hospital

🇵🇰

Karachi, Pakistan

Peoples Medical College Hospital

🇵🇰

Nawabshah, Pakistan

Sri Jayawardenepura CTICU

🇱🇰

Colombo, Sri Lanka

Jaffna Teaching Hospital

🇱🇰

Jaffna, Sri Lanka

Puttlam Hospital

🇱🇰

Puttalam, Sri Lanka

Nakornping Hospital

🇹🇭

Chiang Mai, Thailand

Aga Khan University Hospital MICU

🇵🇰

Karachi, Pakistan

Karapitiya Teaching Hospital

🇱🇰

Galle, Sri Lanka

Doctor's Hospital

🇵🇰

Lahore, Pakistan

National Hospital and Medical Center

🇵🇰

Lahore, Pakistan

Colombo South Teaching Hospital MICU

🇱🇰

Colombo, Sri Lanka

Colombo South Teaching Hospital SICU

🇱🇰

Colombo, Sri Lanka

Sri Jayewardenepura General Hospital GICU

🇱🇰

Colombo, Sri Lanka

National Hospital for Tropical Diseases

🇻🇳

Hanoi, Vietnam

Oxford University Clinical Research Unit

🇻🇳

Ho Chi Minh City, Vietnam

Chulalongkorn University Hospital

🇹🇭

Bangkok, Thailand

Sriraj Hospital

🇹🇭

Bangkok, Thailand

Hospital for Tropical Diseases, Mahidol University

🇹🇭

Bangkok, Thailand

Chiang Mai Hospital Surgical ICU

🇹🇭

Chiang Mai, Thailand

Prince of Songkla University

🇹🇭

Hat Yai, Thailand

© Copyright 2025. All Rights Reserved by MedPath